Glycopyrrolate + Formoterol — Competitive Intelligence Brief

Glycopyrrolate + Formoterol (Glycopyrrolate + Formoterol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist (LAMA) + long-acting beta-2 agonist (LABA) combination. Area: Respiratory / Pulmonology.

marketed Long-acting muscarinic antagonist (LAMA) + long-acting beta-2 agonist (LABA) combination M3 muscarinic receptor; beta-2 adrenergic receptor Respiratory / Pulmonology Small molecule

Target snapshot

Glycopyrrolate + Formoterol (Glycopyrrolate + Formoterol) — Chiesi Farmaceutici S.p.A.. Glycopyrrolate is an anticholinergic agent that blocks muscarinic receptors to reduce airway secretions and bronchoconstriction, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Glycopyrrolate + Formoterol TARGET	Glycopyrrolate + Formoterol	Chiesi Farmaceutici S.p.A.	marketed	Long-acting muscarinic antagonist (LAMA) + long-acting beta-2 agonist (LABA) combination	M3 muscarinic receptor; beta-2 adrenergic receptor
Umeclidinium/Vilanterol 62.5/25 mcgs	Umeclidinium/Vilanterol 62.5/25 mcgs	National Institute of Respiratory Diseases, Mexico	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
Revefenacin 175 µg, Formoterol 20 µg	Revefenacin 175 µg, Formoterol 20 µg	University of Tennessee Graduate School of Medicine	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
Umeclidinium / Vilanterol Dry Powder Inhaler	Umeclidinium / Vilanterol Dry Powder Inhaler	Gary L. Pierce	marketed	Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
Aclidinium bromide & formoterol fumarate	Aclidinium bromide & formoterol fumarate	University of Dundee	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
GSK573719/GW642444 Inhalation Powder	GSK573719/GW642444 Inhalation Powder	GlaxoSmithKline	phase 3	LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist)	M3 muscarinic receptor; beta-2 adrenergic receptor
GSK573719 + GW642444 62.5/25	GSK573719 + GW642444 62.5/25	GlaxoSmithKline	phase 3	Long-acting muscarinic antagonist / long-acting beta-2 agonist (LAMA/LABA combination)	M3 muscarinic receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist (LAMA) + long-acting beta-2 agonist (LABA) combination class)

1. Chiesi Farmaceutici S.p.A. · 1 drug in this class